Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR1 | P30872 | 1/20 | 0.47 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.47 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.47 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.47 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | TACR2 | P21452 | 3/20 | 0.46 |
| ▸ | NT5E | P21589 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 8/20 | 0.43 |
| ▸ | CDC25B | P30305 | 6/20 | 0.43 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.43 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.42 |
| ▸ | GJB2 | P29033 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6892339 | 1.00 | SSTR1 (0.47) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL12083220 | 1.00 | SSTR1 (0.47) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL1521538 | 1.00 | SSTR1 (0.47) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL1764142 | 0.92 | SSTR4 (0.43) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL4906226 | 0.92 | SSTR4 (0.43) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL14672596 | 0.90 | SSTR4 (0.53) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL19272019 | 0.90 | HTR1A (0.43) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL4616594 | 0.89 | HTR1A (0.44) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL19276601 | 0.89 | SSTR4 (0.49) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL19276600 | 0.89 | SSTR4 (0.49) | SSTR1SSTR2SSTR4SSTR3SSTR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906460-B2 | Active-site engineering of nucleotidylyltransferases and general enzymatic methods for the synthesis of natural and “unnatural” UDP- and TDP-nucleotide sugars | SLOAN-KETTERING INSTITUTE FOR CANCER (US) | 2011-03-15 | — | — | US | disclosed |
| US-20070178487-A1 | ACTIVE-SITE ENGINEERING OF NUCLEOTIDYLYLTRANSFERASES AND GENERAL ENZYMATIC METHODS FOR THE SYNTHESIS OF NATURAL AND \"UNNATURAL\" UDP- AND TDP-NUCLEOTIDE SUGARS | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2007-08-02 | — | — | US | disclosed |
| US-7122359-B2 | Active-site engineering of nucleotidylyltransferases and general enzymatic methods for the synthesis of natural and “unnatural” UDP- and TDP-nucleotide sugars | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2006-10-17 | — | — | US | disclosed |
| US-20030055235-A1 | Active-site engineering of nucleotidylyltransferases and general enzymatic methods for the synthesis of natural and \"unnatural\" UDP- and TDP-nucleotide sugars | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2003-03-20 | — | — | US | disclosed |
| WO-2002048331-A2 | ACTIVE-SITE ENGINEERING OF NUCLEOTIDYLTRANSFERASES AND ENZYMATIC METHODS FOR THE SYNTHESIS OF NATURAL AND 'UNNATURAL' UDP- AND NUCLEOTIDE SUGARS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055235-A1 | Active-site engineering of nucleotidylyltransferases and general enzymatic methods for the synthesis of natural and \"unnatural\" UDP- and TDP-nucleotide sugars | PNP, NUDT14, ENTPD5 | SSTR1 4745/4885SSTR2 4834/4885SSTR4 4784/4885 |
| US-20070178487-A1 | ACTIVE-SITE ENGINEERING OF NUCLEOTIDYLYLTRANSFERASES AND GENERAL ENZYMATIC METHODS FOR THE SYNTHESIS OF NATURAL AND \"UNNATURAL\" UDP- AND TDP-NUCLEOTIDE SUGARS | PNP, NUDT14, NUDT5 | SSTR1 4736/4885SSTR2 4824/4885SSTR4 4764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.